Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393931

2023-01-01

Abstract:PDF file - 239K, The interaction of mNrf2 with RXRa in MCF7-RXRa cells.

What problem does this paper attempt to address?

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393940

2023-01-01

Abstract:PDF file - 188K, RXRa interacted with Nrf2 in vivD.
Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393928.v1

2023-01-01

Abstract:PDF file - 288K, The binding of NRF2 to the ARE sites in MCF7 and MCF7-RXRo cells.
Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393946

2023-01-01

Abstract:PDF file - 499K, Recombinant his-RXRa was unable to interact with GST-hNRF2 mutant fusion protein that lacked residues 209-316 between the Neh5 and Neh6 domains.
Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393943

2023-01-01

Abstract:PDF file - 572K, Cellular co-localization of ectopic GFP and RFP in HEK293T cells.
Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393937

2023-01-01

Abstract:PDF file - 160K, tBHQ increased the expression of AKR1C in MCF7 cells.
Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393934

2023-01-01

Abstract:PDF file - 232K, BHA up-regulated ARE-gene battery in mouse small intestine and liver.
Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.22393922

2023-01-01

Abstract:PDF file - 97K, Includes plasmid construction data, GST pull-down assay, and immunoprecipitation data. Also includes supplementary references.
RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Hongyan Wang,Kaihua Liu,Miao Geng,Peng Gao,Xiaoyuan Wu,Yan Hai,Yangxia Li,Yulong Li,Lin Luo,John D. Hayes,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1158/0008-5472.can-12-3386

IF: 11.2

2013-01-01

Cancer Research

Abstract:AbstractThe transcription factor NRF2 (NFE2L2) is a pivotal activator of genes encoding cytoprotective and detoxifying enzymes that limit the action of cytotoxic therapies in cancer. NRF2 acts by binding antioxidant response elements (ARE) in its target genes, but there is relatively limited knowledge about how it is negatively controlled. Here, we report that retinoic X receptor alpha (RXRα) is a hitherto unrecognized repressor of NRF2. RNAi-mediated knockdown of RXRα increased basal ARE-driven gene expression and induction of ARE-driven genes by the NRF2 activator tert-butylhydroquinone (tBHQ). Conversely, overexpression of RXRα decreased ARE-driven gene expression. Biochemical investigations showed that RXRα interacts physically with NRF2 in cancer cells and in murine small intestine and liver tissues. Furthermore, RXRα bound to ARE sequences in the promoters of NRF2-regulated genes. RXRα loading onto AREs was concomitant with the presence of NRF2, supporting the hypothesis that a direct interaction between the two proteins on gene promoters accounts for the antagonism of ARE-driven gene expression. Mutation analyses revealed that interaction between the two transcription factors involves the DNA-binding domain of RXRα and a region comprising amino acids 209-316 in human NRF2 that had not been defined functionally, but that we now designate as the NRF2-ECH homology (Neh) 7 domain. In non–small cell lung cancer cells where NRF2 levels are elevated, RXRα expression downregulated NRF2 and sensitized cells to the cytotoxic effects of therapeutic drugs. In summary, our findings show that RXRα diminishes cytoprotection by NRF2 by binding directly to the newly defined Neh7 domain in NRF2. Cancer Res; 73(10); 3097–108. ©2013 AACR.
Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Jiaguo Wu,Hongyan Wang,Xiuwen Tang

DOI: https://doi.org/10.1016/j.bbrc.2014.08.111

IF: 3.1

2014-01-01

Biochemical and Biophysical Research Communications

Abstract:NF-E2 P45-related factor 2 (Nrf2) is a key transcription factor that controls genes encoding cytoprotective and detoxifying enzymes through antioxidant response elements (AREs) in their regulatory regions. We reported recently that retinoid X receptor alpha (RXR alpha) inhibits Nrf2 function by direct interaction with the Neh7 domain of Nrf2 in a ligand-independent manner. Here, we provide evidence that an RXR alpha-specific ligand, bexarotene, dose-dependently inhibits the mRNA expression of ARE-driven genes. Knock-down of RXR alpha by siRNA abolished the inhibitory effect of bexarotene. Conversely, the overexpression of RXR alpha enhanced the inhibition by bexarotene, indicating that the effect is mediated by RXR alpha. The inhibition by bexarotene was also found in the non-small-cell lung cancer cell line A549, which carries a dysfunctional somatic mutation of Kelch-like ECH-associated protein 1 (KEAP1), suggesting that KEAP1 is not involved. Our results demonstrate that rexinoid is able to inhibit the transcriptional activity of Nrf2, and that RXR alpha can repress the cytoprotection pathway in a ligand-dependent manner. (C) 2014 Elsevier Inc. All rights reserved.
Structural Basis for Retinoic X Receptor Repression on the Tetramer

Haitao Zhang,Lili Chen,Jing Chen,Hualiang Jiang,Xu Shen

DOI: https://doi.org/10.1074/jbc.M111.245498

IF: 5.485

2011-01-01

Journal of Biological Chemistry

Abstract:Retinoic X receptor (RXR) is a master nuclear receptor in the processes of cell development and homeostasis. Unliganded RXR exists in an autorepressed tetramer, and agonists can induce RXR dimerization and coactivator recruitment for activation. However, the molecular mechanisms involving the corepressor recruitment and antagonist-mediated repression of RXR are still elusive. Here we report the crystal structure of RXRα ligand-binding domain (LBD) complexed with silencing mediator for retinoid and thyroid hormone receptors (SMRT) corepressor motif. As the first structural report on the unliganded nuclear receptor bound to the corepressor motif, RXRαLBD-SMRT exhibits a significant structural rearrangement, compared with apoRXRαLBD tetramer. To elucidate further the molecular determinants for RXR repression by its antagonist, we also determine the crystal structure of RXRαLBD-SMRT complexed with the identified antagonist rhein. In the structure, two rhein molecules and two SMRT peptides are in the RXRαLBD tetramer, different from the case in RXRαLBD-SMRT structure, where four SMRT peptides bind to RXRαLBD tetramer. It seems that rhein induces a displacement of SMRT motif by activation function 2 (AF-2) motif binding to the receptor. Combining our current work with the published results, structural superposition of RXRαLBDs in different states reveals that RXR uses an overlapped binding site for coactivator, corepressor, and AF-2 motifs, whereas the AF-2 motif adopts different conformations for agonist or antagonist interaction and coactivator or corepressor recruitment. Taken together, we thus propose a molecular model of RXR repression on the tetramer.
The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

Yulong Li,Hongyan Wang,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1002/1873-3468.12779

2017-01-01

FEBS Letters

Abstract:The NF‐E2 p45‐related factor 2 (NRF2)–Kelch‐like ECH‐associated protein 1 signaling pathway plays an important role in cytoprotection. In acute promyelocytic leukemia, fusion of the promyelocytic leukemia protein (PML) with retinoic acid receptor alpha (RARα) results in an oncogene, PML‐RARα (PR). Although previous studies have shown that both RARα and PML inhibit NRF2 activity, how PR regulates NRF2 has not been reported. Here, we discovered that PR‐S, the short isoform of PR, potentiates NRF2 activity in a tert‐butylhydroquinone (tBHQ) concentration‐dependent manner. Furthermore, PR‐S colocalized with NRF2 in HeLa and HEK293T cells. The association of PR‐S and NRF2 is mediated by the DNA‐binding domains of RARα and the Neh7 domain of NRF2. Our results define a novel function of PR‐S as a NRF2‐transcriptional co‐activator.
Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Xiu Jun Wang,John D. Hayes,Colin J. Henderson,C. Roland Wolf

DOI: https://doi.org/10.1073/pnas.0709483104

2007-01-01

Abstract:Isothiocyanates and phenolic antioxidants can prevent cancer through activation of Nrf2 (NF-E2 p45-related factor 2), a transcription factor that controls expression of cytoprotective genes through the antioxidant response element (ARE) enhancer. Using a human mammary MCF7-derived AREc32 reporter cell line, we now report that all-trans retinoic acid (ATRA), and other retinoic acid receptor alpha (RARalpha) agonists, markedly reduces the ability of Nrf2 to mediate induction of ARE-driven genes by cancer chemopreventive agents including the metabolite of butylated hydroxyanisole, tert-butylhydroquinone (tBHQ). The basal and tBHQ-inducible expression of aldo-keto reductase (AKR) AKR1C1 and AKR1C2 genes, which are regulated by Nrf2, was also repressed by ATRA in AREc32 cells. Antagonists of RARalpha augmented induction of ARE-driven gene expression by tBHQ, as did knockdown of RARalpha by using RNAi. The expression of the ARE-gene battery was increased in the small intestine of mice fed on a vitamin A-deficient diet, and this increase was repressed by administration of ATRA. By contrast, in the small intestine of Nrf2 null mice, the expression of ARE-driven genes was not affected by vitamin A status. In MCF7 cells, ATRA did not block the nuclear accumulation of Nrf2 but reduced the binding of Nrf2 to the ARE enhancer as a consequence of forming a complex with RARalpha. These data suggest that cross-talk between Nrf2 and RARalpha could markedly influence the sensitivity of cells to electrophiles and oxidative stressors and, as a consequence, to carcinogenesis.
Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Xiu Jun Wang,John D. Hayes,C. Roland Wolf

DOI: https://doi.org/10.1158/0008-5472.22366175

2023-01-01

Abstract:Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents
Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Akhileshwar Namani,Yulong Li,Xiu Jun Wang,Xiuwen Tang

DOI: https://doi.org/10.1016/j.bbamcr.2014.05.003

IF: 5.011

2014-01-01

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Abstract:Nuclear factor-erythroid 2 p45-related factor 2 (NRF2, also known as Nfe2l2) plays a critical role in regulating cellular defense against electrophilic and oxidative stress by activating the expression of an array of antioxidant response element-dependent genes. On one hand, NRF2 activators have been used in clinical trials for cancer prevention and the treatment of diseases associated with oxidative stress; on the other hand, constitutive activation of NRF2 in many types of tumors contributes to the survival and growth of cancer cells, as well as resistance to anticancer therapy. In this review, we provide an overview of the NRF2 signaling pathway and discuss its role in carcinogenesis. We also introduce the inhibition of NRF2 by nuclear receptors. Further, we address the biological significance of regulation of the NRF2 signaling pathway by nuclear receptors in health and disease. Finally, we discuss the possible impact of NRF2 inhibition by nuclear receptors on cancer therapy.
Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Wenjie You,Lijun Li,Deqiao Sun,Xueqing Liu,Zongjun Xia,Shan Xue,Bi Chen,Hui Qin,Jing Ai,Handong Jiang

DOI: https://doi.org/10.1158/2326-6066.22539082

2023-01-01

Abstract:Supplementary Table 1, Supplementary Figures 1-7
Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Xiu Jun Wang,John D. Hayes,C. Roland Wolf

DOI: https://doi.org/10.1158/0008-5472.can-06-2298

IF: 11.2

2006-01-01

Cancer Research

Abstract:Abstract The NF-E2 p45-related factor 2 (Nrf2) regulates cytoprotective genes that contain an antioxidant response element (ARE) in their promoters. To investigate whether anticancer drugs can induce ARE-driven gene expression, we have developed a stable human mammary MCF7-derived reporter cell line called AREc32, which contains a luciferase gene construct controlled by eight copies of the cis-element. In these cells, luciferase activity was increased up to 50-fold following treatment with 50 μmol/L tert-butylhydroquinone (t-BHQ). Basal and inducible luciferase activities in AREc32 cells were increased by forced overexpression of Nrf2 and reduced by knockdown of endogenous Nrf2 expression with RNA interference. Depletion of cellular reduced glutathione (GSH) by treatment of AREc32 cells with l-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luciferase activity, but pretreatment with BSO augmented induction of luciferase activity by t-BHQ. Induction of reporter activity by t-BHQ in AREc32 cells was suppressed markedly by the antioxidants N-acetylcysteine and GSH but only modestly by vitamins C or E, suggesting that ARE-luciferase expression is induced primarily by thiol-active electrophiles rather than free radicals. The anticancer drugs cisplatin, etoposide, mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)] weakly induced luciferase activity in AREc32 cells. Moreover, treatment of AREc32 cells with BSO immediately before exposure to anticancer drugs enhanced induction of ARE-driven luciferase activity by cisplatin, BCNU, chlorambucil, and melphalan and also induced endogenous AKR1C (AKR1C refers to AKR1C1 and AKR1C2), a target gene of Nrf2. Our findings show that Nrf2 can be activated by certain anticancer agents, and this will influence the effectiveness of chemotherapy. (Cancer Res 2006; 66(22): 10983-94)
The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains

J-H Kim,S Yu,J D Chen,A N Kong

DOI: https://doi.org/10.1038/onc.2012.59

IF: 8.756

2012-01-01

Oncogene

Abstract:Nuclear factor erythroid 2-related factor 2 (Nrf2, NM 006164, 605 AA) is essential for the antioxidant responsive element (ARE)-mediated expression of a group of detoxifying antioxidant genes that detoxify carcinogens and protect against oxidative stress. Several proteins have been identified as Nrf2-interacting molecules. In this study, we found that the overexpression of receptor-associated coactivator 3 (RAC3)/AIB-1/steroid receptor coactivator-3, a nuclear coregulator and oncogene frequently amplified in human breast cancers, induced heme oxygenase-1 (HO-1) through Nrf2 transactivation in HeLa cells. Next, we determined the interaction between RAC3 and Nrf2 proteins using a co-immunoprecipitation assay and fluorescence resonance energy transfer analysis. The results showed that RAC3 bound directly to the Nrf2 protein in the nucleus. Subsequently, we identified the interacting domains of Nrf2 and RAC3 using a glutathione S-transferase pull-down assay. The results showed that both the N-terminal RAC3-pasB and C-terminal RAC3-R3B3 domains were tightly bound to the Neh4 and Neh5 transactivation domains. Furthermore, chromatin immunoprecipitation showed that RAC3 bound tightly to the ARE enhancer region of the HO-1 promoter via Nrf2 binding. These data suggest that Nrf2 activation is modulated and directly controlled through interactions with the RAC3 protein in HeLa cells.
NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell

Fan Chen,Jiebo Chen,Jiacheng Lin,Anton V. Cheltsov,Lin Xu,Ya Chen,Zhiping Zeng,Liqun Chen,Mingfeng Huang,Mengjie Hu,Xiaohong Ye,Yuqi Zhou,Guanghui Wang,Ying Su,Long Zhang,Fangfang Zhou,Xiao-kun Zhang,Hu Zhou

DOI: https://doi.org/10.1007/s13238-015-0178-9

2015-01-01

Protein & Cell

Abstract:BSTRACT Retinoid X receptor α (RXRα) and its N-terminally truncated version tRXRα play important roles in tumorigenesis, while some RXRα ligands possess potent anti-cancer activities by targeting and modulating the tumorigenic effects of RXRα and tRXRα. Here we describe NSC-640358 (N-6), a thiazolyl-pyrazole derived compound, acts as a selective RXRα ligand to promote TNFα-mediated apoptosis of cancer cell. N-6 binds to RXRα and inhibits the transactivation of RXRα homodimer and RXRα/TR3 heterodimer. Using mutational analysis and computational study, we determine that Arg316 in RXRα, essential for 9- cis -retinoic acid binding and activating RXRα transactivation, is not required for antagonist effects of N-6, whereas Trp305 and Phe313 are crucial for N-6 binding to RXRα by forming extra π–π stacking interactions with N-6, indicating a distinct RXRα binding mode of N-6. N-6 inhibits TR3-stimulated transactivation of Gal4-DBD-RXRα-LBD by binding to the ligand binding pocket of RXRα-LBD, suggesting a strategy to regulate TR3 activity indirectly by using small molecules to target its interacting partner RXRα. For its physiological activities, we show that N-6 strongly inhibits tumor necrosis factor α (TNFα)-induced AKT activation and stimulates TNFα-mediated apoptosis in cancer cells in an RXRα/tRXRα dependent manner. The inhibition of TNFα-induced tRXRα/p85α complex formation by N-6 implies that N-6 targets tRXRα to inhibit TNFα-induced AKT activation and to induce cancer cell apoptosis. Together, our data illustrate a new RXRα ligand with a unique RXRα binding mode and the abilities to regulate TR3 activity indirectly and to induce TNFα-mediated cancer cell apoptosis by targeting RXRα/tRXRα.
Liganded retinoic acid X receptor α represses connexin 43 through a potential retinoic acid response element in the promoter region

Ruoyi Gu,Jun Xu,Yixiang Lin,Jing Zhang,Huijun Wang,Wei Sheng,Duan Ma,Xiaojing Ma,Guoying Huang

DOI: https://doi.org/10.1038/pr.2016.47

IF: 3.953

2016-01-01

Pediatric Research

Abstract:Introduction: Retinoic acid X receptor alpha ( RXRα ) and Connexin 43 ( Cx43 ) both play a crucial role in cardiogenesis. However, little is known about the interplay mechanism between the RXRα and Cx43 . Methods: The activations of retinoic acid response element (RARE) in Cx43 were measured by luciferase transfection assay. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) was performed to prove that RXRα can directly bind to the RARE sequence. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to analyze the RXRα and Cx43 mRNA level and protein level in cells. Results: In this study, we confirmed the negative association of the gene expression between the RXRα and Cx43 in the cell level. Interestingly, a functional RARE was detected in the region from −1,426 to −314 base pairs upstream from the transcriptional start site of Cx43 . Moreover, we also prove that RXRα can directly bind to this RARE sequence in vitro and in vivo . Conclusions: RXRα negatively regulates the transcription and expression by directly binding to the RARE in the promoter of Cx43 . The RARE-like sequence harbored in the Cx43 promoter region may serve as a functional RARE in the retinoic acid (RA) signaling pathway.
Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343

Kayo Yukawa-Takamatsu,Yifei Wang,Masaki Watanabe,Yuta Takamura,Michiko Fujihara,Mariko Nakamura-Nakayama,Shoya Yamada,Shota Kikuzawa,Makoto Makishima,Mayu Kawasaki,Sohei Ito,Shogo Nakano,Hiroki Kakuta

DOI: https://doi.org/10.1021/acs.jmedchem.0c01883

IF: 8.039

2020-12-30

Journal of Medicinal Chemistry

Abstract:Retinoid X receptor (RXR) modulators (rexinoids) are considered to have therapeutic potential for multiple diseases, such as Alzheimer's disease and Parkinson's disease. To overcome various disadvantages of prior screening methods, we previously developed an RXR binding assay using a fluorescent RXR ligand, CU-6PMN (4). However, this ligand binds not only at the ligand-binding domain (LBD) but also at the dimer–dimer interface of hRXRα. Here, we present a new fluorescent RXR antagonist 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(11-oxo-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxamido)phenyl)amino]nicotinic acid (NEt-C343, 7), which emits strong fluorescence only when bound to the RXR-LBD. It allows us to perform a rapid, simple, and nonhazardous binding assay that does not require bound/free separation and uses a standard plate reader. The obtained Ki values of known compounds were correlated with the Ki values obtained using the standard [3H]9cis-retinoic acid assay. This assay should be useful for drug discovery as well as for research on endocrine disruptors, functional foods, and natural products.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01883?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01883</a>.Preparation of human RXRα-LBD, creation of human RXRα ligand-binding domain (LBD) coordinates, coordinates for compounds (input files), creating the grid box, creating input files and log files of docking simulations, calculation of the Z′ factor, statistical analysis, Schild analysis of 6 and 7 for hRXRα, transactivation of hRXR subtypes by 17 in the absence or presence of 7, UV–vis absorbance and fluorescence spectra of fluorescein and 7, relative fluorescence intensity data of 100 nM 7 in various solvents, chemical structure of CBTF-EE (19), binding assay protocol for rexinoids using 7 (λEx = 430 nm/λEm = 535 nm), time course of Z′ factors during the competitive binding assay using 100 nM 7 with 500 nM hRXRα-LBD, chemical structures of rexinoids in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>B and natural ligands in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>C, fluorescence binding assay using 7 (λEx = 485 nm/λEm = 535 nm), Schild plot slopes for 6 and 7 against 17, calculated Ki values obtained with 4, 7, and 9cis-RA, lists of PDB files, supporting movie legend, NMR spectra and HPLC charts (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_001.pdf">PDF</a>)Binding model of 7 (green stick model) in the antagonistic form with RXRα-LBD (PDB code: 3A9E) on AutoDock vina (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_002.mov">MOV</a>)RXR_LBD 3A9E.pdb (chain A from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_003.pdb">PDB</a>)Cpnd 5_mode1.pdb (mode 1 structure of NEt-SB (5) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_004.pdb">PDB</a>)Cpnd 6_mode1.pdb (mode 1 structure of NEt-BA (6) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_005.pdb">PDB</a>)Cpnd 6_mode2.pdb (mode 1 structure of NEt-BA (6) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_006.pdb">PDB</a>)Cpnd 7_mode1.pdb (mode 1 structure of NEt-C343 (7) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_007.pdb">PDB</a>)Cpnd 7_mode6.pdb (mode 6 structure of NEt-C343 (7) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_008.pdb">PDB</a>)LG_3A9E.pdb (binding structure of LG100754 (18) "754" from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_009.pdb">PDB</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_010.csv">CSV</a>)This article has not yet been cited by other publications.

chemistry, medicinal

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Structural Basis for Retinoic X Receptor Repression on the Tetramer

The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains

NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell

Liganded retinoic acid X receptor α represses connexin 43 through a potential retinoic acid response element in the promoter region

Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343